WHO allocates 70,000 Ebola vaccine doses to DRC as outbreak escalates

The Democratic Republic of Congo will receive 70,000 doses of Ervebo vaccine as health authorities move to contain a devastating Ebola virus outbreak that has reached unprecedented scale. The WHO confirmed the vaccine allocation as new infections continue to emerge across affected regions in the central African nation.

The current outbreak represents the largest Ebola epidemic recorded in the DRC since the virus was first identified in the country in 1976. With nearly 2,500 deaths already recorded, the surge in cases has prompted an urgent international health response aimed at preventing further transmission.

Ervebo, developed by Merck, has proven effective in controlling Ebola spread when deployed rapidly in outbreak zones. The vaccine works by inducing immune response before potential exposure, making mass vaccination campaigns critical in halting disease progression through affected populations.

The allocation underscores the global health community's growing concern over the outbreak's trajectory. Vaccination efforts will complement existing containment measures, including isolation protocols, contact tracing, and supportive care for confirmed cases. Health officials have emphasized that rapid deployment of the vaccine supply remains essential to reversing the outbreak's momentum.